Expression of CD44S and CD44v5 Is More Common in Stage III Than in Stage I Serous Ovarian Carcinomas-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Expression of CD44S and CD44v5 Is More Common in Stage III Than in Stage I Serous Ovarian Carcinomas

Published:2001-12 Issue:4 Volume:9 Page:309-314
ISSN:1541-2016
Container-title:Applied Immunohistochemistry & Molecular Morphology
language:en
Short-container-title:Applied Immunohistochemistry & Molecular Morphology

Author:

Afify Alaa M.,Ferguson Amy W.,Davila Rosa M.,Werness Bruce A.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Medical Laboratory Technology,Histology,Pathology and Forensic Medicine

Reference30 articles.

1. Expression of cell adhesion molecules on ovarian tumour cell lines and mesothelial cells, in relation to ovarian cancer metastasis

2. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons.

3. Splicing choice from ten variant exons establishes CD44 variability

4. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Prognostic Value of Cancer Stem Cell Markers (CSCs) Expression—ALDH1A1, CD133, CD44—For Survival and Long-Term Follow-Up of Ovarian Cancer Patients;International Journal of Molecular Sciences;2023-01-25

2. CD44 in Ovarian Cancer Progression and Therapy Resistance—A Critical Role for STAT3;Frontiers in Oncology;2020-12-01

3. CD44 Immunoexpression is Unfavorable Predictor in Ovarian Serous Cancer;Applied Immunohistochemistry & Molecular Morphology;2018-07

4. Peritoneal dissemination of ovarian cancer: role of MUC16-mesothelin interaction and implications for treatment;Expert Review of Anticancer Therapy;2017-12-21

5. CD44 as a cancer stem cell marker and its prognostic value in patients with ovarian carcinoma;Journal of Obstetrics and Gynaecology;2017-08-17

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3